Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.81 |
| ▸ | RECQL | P46063 | 1/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | PDE4A | P27815 | 1/20 | 0.54 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.54 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16093290 | 0.98 | SMN1; SMN2 (0.79) | SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4 | |
| SCHEMBL13845977 | 0.98 | SMN1; SMN2 (0.79) | SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4 | |
| SCHEMBL4068438 | 0.98 | SMN1; SMN2 (0.79) | SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4 | |
| SCHEMBL5452364 | 0.96 | SMN1; SMN2 (0.75) | SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4 | |
| SCHEMBL12418058 | 0.93 | SMN1; SMN2 (0.71) | SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4 | |
| SCHEMBL4071039 | 0.92 | SMN1; SMN2 (0.68) | SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4 | |
| SCHEMBL11253764 | 0.89 | SMN1; SMN2 (0.65) | SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4 | |
| Toluene SCHEMBL27696348 | 0.87 | ALDH1A1 (0.73) | SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4 | |
| SCHEMBL23093579 | 0.84 | KDM4E (0.58) | SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4 | |
| SCHEMBL24477877 | 0.84 | SMN1; SMN2 (0.58) | SMN1; SMN2KDM4ERECQLALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150339-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2024-05-09 | — | — | US | disclosed |
| EP-4291557-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | Mironid Limited (GB) | 2023-12-20 | — | — | EP | disclosed |
| EP-3554503-B1 | INHIBITORS OF BROMODOMAIN-CONTAINING PROTEIN 4 (BRD4) | UNIV TEXAS (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-3554503-B1 | INHIBITORS OF BROMODOMAIN-CONTAINING PROTEIN 4 (BRD4) | UNIV TEXAS (US) | 2023-10-04 | — | — | EP | disclosed |
| CN-116848107-A | Compounds and their use as PDE4 activators | 米罗尼德有限公司 | 2023-10-03 | — | — | CN | disclosed |
| WO-2022172037-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | MIRONID LIMITED (GB) | 2022-08-18 | — | — | WO | disclosed |
| US-11117865-B2 | Inhibitors of bromodomain-containing protein 4 (BRD4) | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-09-14 | — | — | US | disclosed |
| US-11117865-B2 | Inhibitors of bromodomain-containing protein 4 (BRD4) | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-09-14 | — | — | US | disclosed |
| EP-3554503-A1 | INHIBITORS OF BROMODOMAIN-CONTAINING PROTEIN 4 (BRD4) | Zhou, Jia (US) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018112037-A1 | INHIBITORS OF BROMODOMAIN-CONTAINING PROTEIN 4 (BRD4) | ZHOU JIA (US) | 2018-06-21 | — | — | WO | disclosed |
| WO-2018112037-A1 | INHIBITORS OF BROMODOMAIN-CONTAINING PROTEIN 4 (BRD4) | ZHOU JIA (US) | 2018-06-21 | — | — | WO | disclosed |
| CN-106146358-B | Method for synthesizing amino- (N-alkyl) benzene sulfonamide | 南京理工大学 | 2018-01-23 | — | — | CN | disclosed |
| CN-106146358-A | Method for synthesizing amino- (N-alkyl) benzene sulfonamide | 南京理工大学 | 2016-11-23 | — | — | CN | disclosed |
| US-20090233878-A1 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | CREDIT SUISSE AG | 2009-09-17 | — | — | US | disclosed |
| US-20090233878-A1 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | CREDIT SUISSE AG | 2009-09-17 | — | — | US | disclosed |
| US-20090233878-A1 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | CREDIT SUISSE AG | 2009-09-17 | — | — | US | disclosed |
| US-7511133-B2 | Adenosine A3 receptor agonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511133-B2 | Adenosine A3 receptor agonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511133-B2 | Adenosine A3 receptor agonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20050250729-A1 | Novel adenosine A3 receptor agonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233878-A1 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | ADORA3, ADORA1, ADORA2A | SMN1; SMN2 3431/4885KDM4E 3083/4885RECQL 637/4885 |
| US-20050250729-A1 | Novel adenosine A3 receptor agonists | ADORA3, ADORA2A, ADORA1 | SMN1; SMN2 2771/4885KDM4E 3299/4885RECQL 958/4885 |
| US-20240150339-A1 | Compounds and Their Use as PDE4 Activators | PDE4A, PDE4B, PDE4C | SMN1; SMN2 1885/4885KDM4E 1809/4885RECQL 234/4885 |
| US-11117865-B2 | Inhibitors of bromodomain-containing protein 4 (BRD4) | BRD4, NFKBIA, NFRKB | SMN1; SMN2 3064/4885KDM4E 798/4885RECQL 3855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.